January 13, 2026 (Edison, NJ): As the market surges for botanicals targeting women’s health, new clinical findings set Xeya Modern Shatavari™ apart in the rapidly expanding category. NXT USA is pleased to report that a peer-reviewed study published in Food & Nutrition Research shows that the standardized extract significantly improves ovarian morphology and androgen-related symptoms, with supportive improvements in hormonal balance and insulin sensitivity among reproductive-aged women from 20-35 years old.
This new publication follows a study published in July 2025 demonstrating benefits for perimenopausal women, making Xeya one of the only Shatavari ingredients with gold-standard, double-blind, placebo-controlled clinical trials in two distinct life stages. Together, these studies position Xeya as one of the industry’s most validated solutions for women’s hormonal health.
“Many women don’t realize how deeply hormonal imbalance can influence reproductive health, metabolism, and skin,” said Eric Anderson, Managing Director of NXT USA. “Xeya Modern Shatavari supports natural hormone balance, helping promote healthy ovarian function, consistent cycles, and hormonal markers tied to clear skin and metabolic resilience.”
Supplement brands addressing Polycystic Ovary Syndrome, or PCOS, are under pressure to deliver more than symptom cover-up. Clinicians and consumers are actively looking for plant-based, clinically validated solutions that address ovarian health, hormones, and metabolism together. Xeya Modern Shatavari now has a published randomized, double‑blind, placebo‑controlled clinical trial in women with PCOS that directly supports this positioning.
Key outcomes from the 12-week PCOS study, which studied 60 women aged 20-35 years old for 84 days:
- Ovarian health: Improvements in polycystic ovarian morphology.
21% reduction in ovarian volume
• 41% reduction in cyst size
• 20–25% reduction in follicle count - Hormonal balance:
33.9% reduction in total testosterone
• 31.8% increase in SHBG (Sex Hormone-Binding Globulin)
• 18.6% improvement in LH:FSH ratio (Luteinizing Hormone:Follicle-Stimulating Hormone) - Metabolic support:
14% improvement in insulin sensitivity (HOMA-IR: Homeostatic Model Assessment of Insulin Resistance) - Visible physical improvements:
44% reduction in acne severity
• 46% reduction in hirsutism
• Reductions in waist and hip circumference - Menstrual regularity:
Improvements in menstrual cycle consistency over baseline
Xeya Modern Shatavari was well-tolerated, with no serious adverse events reported.
For finished product brands, Xeya Modern Shatavari offers a differentiated, clinically substantiated ingredient that can anchor PCOS and menstrual health formulas, women’s metabolic and hormone-balance products, and skin-hair/hormone “PCOS beauty-from-within” concepts.
This new publication reinforces NXT USA’s commitment to rigorous science. Xeya stands on NXT USA’s Four Pillars of Validation, a comprehensive design of human clinical studies that includes the following four bedrock principles:
- Patient Responses—Participants reported measurable improvements in skin clarity, hair growth, and cycle regularity.
- Physician Assessments—Expert eyes confirmed improved skin, hair, and menstrual patterns.
- Biomarker Analysis—Objective improvements measured in testosterone, SHBG, LH/FSH, and insulin resistance.
- Physical Measurements—Tangible reductions in ovarian volume, cyst size, and follicle count.
“This approach provides a degree of validation unmatched among Shatavari suppliers,” said Anderson. “This framework turns good studies into great ones, and good claims into claims that can build a supplement brand. This approach is exactly why brands—big brands—choose to partner with us.”
Beyond clinical rigor, Xeya is produced through a fully traceable and environmentally responsible supply chain. The Shatavari is wildcrafted under regulated forest management, peeled and dried by local women’s cooperatives, and processed using only purified water and organic ethanol. Final extraction and manufacturing follow low-carbon, contaminant-free practices and carry globally recognized certifications, ensuring sustainability, safety, and consistency from forest to formulation.
While all other Shatavari (Asparagus racemosus) formulations rely on higher daily doses, Xeya delivers significant outcomes at just 100 mg, highlighting NXT USA’s leadership in low-dose, clinically validated Shatavari formulations. This low dose opens new formulation opportunities across capsules, gummies, powders, beverages, and ready-to-eat formats—offering brand partners more flexibility and lower cost-per-serving while maintaining evidence-based efficacy.
As interest in Shatavari surges across the nutraceutical industry, Xeya Modern Shatavari stands out for more than its newly published findings among women with PCOS—the leading cause of reproductive failure and metabolic dysfunction in women of reproductive age. With an additional peer-reviewed study already published on perimenopause, Xeya is clinically validated in two distinct phases of women’s health—and at a fraction of the dose used by competing ingredients. While other suppliers are testing 300 mg, 500 mg, or higher, Xeya delivers significant outcomes assessed in human clinical studies at just 50 mg or 100 mg, making it the low-dose leader and thus the most formulator-friendly Shatavari extract on the market.
These advantages position NXT USA and Xeya Modern Shatavari at the forefront of clinically proven, responsibly sourced botanical innovation for women’s health.
Reference:
Kondamudi S., Sadu S., Deva S., Yalamanchi A., & Yalamanchi A. (2025). CL22209, a standardized Asparagus racemosus root extract, demonstrates improved ovarian morphology, menstrual regularity, and metabolic parameters in women with polycystic ovary syndrome in a randomized, controlled trial. Food & Nutrition Research, 69. https://doi.org/10.29219/fnr.v69.13244
Media Inquiries:
Becky Wright
Wright On Marketing & Communications
201-675-0197
About NXT USA:
NXT USA is a leader in science-driven nutraceutical innovation, dedicated to developing clinically validated, proprietary ingredient formulations that address real-world health needs. The company’s founders bring decades of experience launching category-defining products such as MenaQ7® Vitamin K2, krill oil, and TamaFlex®. Today, NXT USA’s portfolio includes award-winning ingredients for joint, digestive, and women’s health—each supported by its Four Pillars of Validation framework: clinical data, measurable outcomes, visible improvements, and real consumer impact. Its latest innovation, Xeya Modern Shatavari™, embodies this mission—bridging Ayurvedic tradition and modern clinical science to deliver balance through every stage of a woman’s life. Learn more at www.nxt-usa.com
About Xeya Modern Shatavari™
Xeya Modern Shatavari™ is a clinically studied extract of Shatavari (Asparagus racemosus), offering a science-backed solution that naturally restores hormonal balance. Developed for efficacy and validated through rigorous clinical trials, Xeya Modern Shatavari supports women’s reproductive and hormonal health, including menstrual regularity and skin-related concerns, from early adulthood through menopause.
About Laila Nutra Private Ltd
Laila Nutra specializes in the development and production of standardized botanical extracts, pharmaceuticals, and functional ingredients, serving both domestic and international markets. With a strong focus on R&D and product innovation, Laila Nutra has built a robust portfolio of patents and scientific achievements, becoming a trusted partner for leading pharmaceutical and wellness brands across more than 25 countries. The company’s facilities operate under strict quality certifications and comply with international standards, cementing its reputation for reliability and excellence in the life sciences sector. Laila Nutra continues its mission to create a healthier future through nature-inspired solutions and scientific rigor.
Xeya Modern Shatavari is a trademark of Laila Nutra Private Ltd.
